Project Grant R01HL175284
Award Date 8/5/25
Completion Date 5/31/29
Dollars Obligated $1.4M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This $385,381 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of dynamic biological hydrogels to modulate cardiac remodeling following myocardial infarction. The primary goals are to: 1) Improve the mechanical stability and stiffness of cardiac extracellular matrix hydrogels compared to existing therapies, and 2) Leverage changes in extracellular matrix composition to promote a more regenerative...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $742,323 to Vanderbilt University to develop a new bioprosthetic aortic valve made from the pulmonary visceral pleura (PVP) tissue. The research aims to demonstrate the PVP valve's superior mechanical durability, calcification resistance, and hemodynamic performance compared to current bioprosthetic valves, in order to improve the long-term durability of...
- This $702,534 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at Texas A&M Engineering Experiment Station (Tees) to develop an integrated super-resolution cardiac magnetic resonance imaging-deep learning (CMR-DL) technology. The goal is to isolate and quantify the contributions of passive and active mechanisms to impaired left ventricular relaxation, a key driver of left ventricular diastolic dysfunction...
- This federal Project Grant award of $758,862.00 was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Yale University. The award supports research aimed at preventing cardiac remodeling and progressive heart failure following myocardial infarction (MI). Key objectives include developing a percutaneous, image-guided approach to deliver hydrogels of varying stiffness to the infarcted and peri-infarcted myocardium. This is intended to...
- The National Heart Lung and Blood Institute awarded a $414,982 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas, Fayetteville Division, Office of Research & Sponsored Programs. The grant aims to enhance a surgical planning tool for heart valve procedures by developing a force-validated computational model of the mitral valve using experimental data from both healthy porcine and human valves. This research will improve the...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $496,255 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Vivita Technologies, Inc. (Davis, CA) to validate its patented SPEAR Platform™ technology for developing unfixed, immune-compatible, and regenerative xenogeneic biomaterials for transcatheter heart valve replacements. The project aims to produce BARE™ patches derived from porcine pericardium that can avoid immune rejection, integrate with...
- This $298,368 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a novel device for treating mitral valve regurgitation. The project aims to optimize the device design and procedure through bench testing, followed by acute in vivo studies to demonstrate the feasibility of the approach. The funding recipient, Link Medical LLC, has invented a catheter-based technology intended to restore proper mitral...
- This Project Grant award, valued at $498,991.40, was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas, Fayetteville. The goal is to engineer microphysiological systems with tight oxygen control to investigate the molecular pathways activated in oxygen gradients and the resulting effects on cardiomyocyte function, in order to obtain a comprehensive understanding of the cardiac response to hypoxic...
- This $363,160 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the University of Texas Southwestern Medical Center (UT Southwestern) to develop bioresorbable heart valves. The award period runs from March 1, 2025 to February 28, 2027. As a highly regarded federal contractor and grantee, UT Southwestern has a strong track record of delivering specialized medical services and innovative biomedical research...
- This $262,138 Project Grant award from the National Science Foundation's Engineering program (CFDA 47.041) supports research at the University of Houston to investigate the mechanisms of cardiac fibrosis, a type of scarring in the heart that leads to impaired function. The key objectives are to: 1) determine the role of the endothelial-mesenchymal transition in cardiac fibrosis, and 2) develop a 3D cardiac fibrosis model to study tissue remodeling. The research will leverage a...